Skip to content
- Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
- Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
- Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
- Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis.
- Cordeiro Mitchell CN, McGuinness B, Fine E, Kearns WG, Christianson MS, Segars J, Pastore LM.
- J Assist Reprod Genet. 2020 Mar 24. doi: 10.1007/s10815-020-01745-2. [Epub ahead of print]
- Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer.
- You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M, Liang Z.
- Front Oncol. 2020 Mar 10;10:295. doi: 10.3389/fonc.2020.00295. eCollection 2020.
- Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer.
- Knowlson C, Haddock P, Bingham V, McQuaid S, Mullan PB, Buckley NE.
- Ther Adv Med Oncol. 2020 Mar 9;12:1758835920906047. doi: 10.1177/1758835920906047. eCollection 2020.